RE:RE:For what it is worthWell I think you are mixing thoughts that are unrelated, so lets see what I can clear up. Firstly the delay in the unaudited 2nd quater numbers I believe was quite lame. Look, you have the numbers the market wasn't expecting anything positive so release them. That was a management error in hindsight. The COVID bit while true was a lame excuse to delay the numbers.
Leadership has two contexts here, firstly, to claim you are a leader in an marketspace you can only make that claim if you meet all the criteria set forth by the market. What does the marketplace say you need to be a leader. These points are laid out in my earlier post and MedX states that this is what the market demands and that they can check off every one of these demands. That defines MedX and unless another competitor can match that claim then MedX is the leader in teledermatology.
Secondly, the other type of leadership is management leadership. Can they lead the company and become a highly profitable company? Well they seem to have developed a globally scalable teledermatology platform so they have listened to the market and created a "best in breed" offering, they were able to fund it so that is also a function of leadership the ability to raise capital, they have been able to attract top sales executives that are seasoned so they must like where the management is leading this company and they must also believe they can sell MedX's offering.So the only thing missing is for the revenue numbers to start to show and for a few large scale deals to show in a press release.
I would say this is a extremely focused team and they have no more reasons not to show all shareholders they know how to drive sales. So lets see how the next few months go.
Remember, telemedicine companies have been around for a while it took the COVID pandemic to alert investors of their leverage and efficency. This will now trikle down to specialty telemedicine companies in my opinion and MedX is the leader in this space.